Targeting Critical Immune Drivers of
Cancer and Inflammation
FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of best-in-class, oral small molecule therapeutics for the treatment of cancer and inflammatory diseases. We leverage big data and proprietary informatics together with advanced drug discovery capabilities to identify novel therapeutics. We target key junctions in pathways that propagate an abnormal immune response. Additionally, our deep insights into disease biology enables us to select patients most likely to respond to our therapies through the use of specific biomarkers. We expect to revolutionize and advance the treatment of cancer and immune-related disorders.